

CLAIMS

1. A pyrazolopyrimidine ester compound, characterized in being of the following general structural formula:



where R is $-(CH_2)_3CH_3$.

2. A method of preparation of the pyrazolopyrimidine ester compound according to claim 1, characterized in taking 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one as a starting material and obtaining a target compound from its reaction with a corresponding chloroformate, which is represented by the following equation:



where R is $-(CH_2)_3CH_3$.

3. The method of preparation according to claim 2, characterized in comprising the steps of:

adding the starting material 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one, the chloroformate and a solvent to a reactor; and after the starting material and the chloroformate are dissolved in the solvent, adding a base to trigger the reaction.

4. The method of preparation according to claim 2, characterized in comprising the steps of:

adding the starting material 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one, a solvent and a base to a reactor; and after the starting material and the base are dissolved in the solvent, adding the chloroformate to trigger the reaction,

wherein with the starting material being taken as a reference, the base is added at an amount of 6.0±0.5 eq. and the chloroformate is added at an amount of 2.0±0.5 eq., and wherein the chloroformate is added, after being dissolved in the solvent, at 0-10 ℃ to trigger the reaction.

5. Use of the pyrazolopyrimidine ester compound according to claim 1, in the manufacture of a medicament for treating lymphoma and lymphocytic leukemia.